| GILEAD |
GILEAD |
92%
|
Revenues from Gilead accounted for 88 % and 100 % of Total revenues for the three months ended March 31, 2026 and 2025, respectively. |
| TAIHO |
TAIHO |
90%
|
License and development services revenue consists of amounts recognized from the portions of the nonrefundable upfront payments received from Gilead and Taiho |
| AZN |
AstraZeneca PLC |
72%
|
nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along with Gilead’s internal manufacturing infra… |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from RCUS graph: nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue … |
| CLDX |
Celldex Therapeutics, Inc. |
72%
|
Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: ny of our investigational products … |
| CLDX |
Celldex Therapeutics, Inc. |
72%
|
ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| GILD |
Gilead Sciences, Inc. |
72%
|
hase Agreement Amendment; and $ million deferred revenue remaining from the First Gilead Collaboration Agreement Amendment effective December 2021. We determined the entire $ million to be the alloca… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from GILD g… |
| HTGC |
Hercules Capital, Inc. |
72%
|
Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from HTGC g… |
| HTGC |
Hercules Capital, Inc. |
72%
|
non-public information and for complying with our disclosure obligations under the Regulation FD. Such disclosures will be included on the company’s website under the heading "Investors & Media." Acc… |
| IPHA |
Innate Pharma S.A. |
72%
|
Reciprocal relationship from IPHA graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from RCUS graph: ny of our investigational products … |
| IPHA |
Innate Pharma S.A. |
72%
|
ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| MRK |
Merck & Co., Inc. |
72%
|
nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along with Gilead’s internal manufacturing infra… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from RCUS graph: nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue … |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from REGN g… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| SNYNF |
Sanofi |
72%
|
ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from SNYN… |
| ABMUNO-THERAPEUTICS-LLC |
ABMUNO-THERAPEUTICS-LLC |
62%
|
h 31, 2026 and 2025. 10 Table of Contents Abmuno License In 2016, we entered into an agreement (the "Abmuno Agreement") with Abmuno Therapeutics LLC ("Abmuno"), under which we obtained the exclusive … |
| BEIGENE-LTD |
BEIGENE-LTD |
62%
|
nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along with Gilead’s internal manufacturing infra… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
ith Hercules at the end of the second quarter 2025. Income Tax Expense There was no Income tax expense for the three months ended March 31, 2026 or 2025 due to forecasted full year NOLs. Liquidity an… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating re… |
| TAIHO-PHARMACEUTICAL-CO-LTD |
TAIHO-PHARMACEUTICAL-CO-LTD |
62%
|
ments In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03 — Income Statement — Reporting Comprehensive Income — Expense Disaggregati… |
| WUXI-BIOLOGICS-IRELAND-LIMITED |
WUXI-BIOLOGICS-IRELAND-LIMITED |
62%
|
ments In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03 — Income Statement — Reporting Comprehensive Income — Expense Disaggregati… |
